All In Biotech

Drug Trial Radar · NCT07696091

Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet

A Single-center, Single-sequence, Self-controlled Open Design Study , to Investigate the Effects of Rifampicin and Clarithromycin on the Pharmacokinetics of RSS0343.

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.

Conditions

  • Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease

Interventions

  • RSS0343 Tablet; Rifampicin CapsulesDrug

    RSS0343 Tablet; Rifampicin Capsules

  • RSS0343 Tablet; Clarithromycin TabletsDrug

    RSS0343 Tablet; Clarithromycin Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax; The maximum plasma concentrationTime frame: Day1-Day38
  2. AUC0-t; From time 0 to the area under the blood drug concentration-time curve corresponding to the last quantifiable concentrationTime frame: Day1-Day38
  3. AUC0-inf;Area under the concentration curve from time 0 to extrapolated infinite timeTime frame: Day1-Day38

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.